GUOBANG PHARMA LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.93 CNY | -0.22% |
|
-0.72% | +2.11% |
| Apr. 15 | Guobang Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Jan. 27 | Guobang Pharma Ltd. announces an Equity Buyback for CNY 200 million worth of its shares. | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 16,111 | 14,792 | 9,813 | 9,960 | - | - |
| Enterprise Value (EV) 1 | 16,111 | 14,792 | 9,813 | 9,960 | 9,960 | 9,960 |
| P/E ratio | 20.9 x | 16 x | 16 x | 13.9 x | 8.92 x | 9.74 x |
| Yield | - | 2.27% | 1.71% | 3.51% | 4.13% | - |
| Capitalization / Revenue | - | 2.59 x | 1.83 x | 1.69 x | 1.32 x | 1.37 x |
| EV / Revenue | - | 2.59 x | 1.83 x | 1.69 x | 1.32 x | 1.37 x |
| EV / EBITDA | - | 11.3 x | 9.59 x | 8.95 x | 7.67 x | 6.65 x |
| EV / FCF | - | 63.8 x | -47.5 x | 53.5 x | 11 x | - |
| FCF Yield | - | 1.57% | -2.11% | 1.87% | 9.12% | - |
| Price to Book | - | 2.07 x | 1.32 x | 1.25 x | 1.1 x | 1.05 x |
| Nbr of stocks (in thousands) | 558,824 | 558,824 | 558,824 | 555,508 | - | - |
| Reference price 2 | 28.83 | 26.47 | 17.56 | 17.93 | 17.93 | 17.93 |
| Announcement Date | 4/15/22 | 4/9/23 | 4/15/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 5,721 | 5,349 | 5,907 | 7,521 | 7,251 |
| EBITDA 1 | - | 1,313 | 1,023 | 1,113 | 1,299 | 1,497 |
| EBIT 1 | - | 1,053 | 702.3 | 825 | 1,284 | 1,187 |
| Operating Margin | - | 18.4% | 13.13% | 13.97% | 17.08% | 16.37% |
| Earnings before Tax (EBT) 1 | - | 1,036 | 697.6 | 830 | 987 | 1,182 |
| Net income 1 | 706 | 920.9 | 612.5 | 722 | 1,120 | 1,028 |
| Net margin | - | 16.1% | 11.45% | 12.22% | 14.89% | 14.18% |
| EPS 2 | 1.380 | 1.650 | 1.100 | 1.290 | 2.010 | 1.840 |
| Free Cash Flow 1 | - | 231.7 | -206.8 | 186 | 908 | - |
| FCF margin | - | 4.05% | -3.87% | 3.15% | 12.07% | - |
| FCF Conversion (EBITDA) | - | 17.65% | - | 16.71% | 69.9% | - |
| FCF Conversion (Net income) | - | 25.16% | - | 25.76% | 81.11% | - |
| Dividend per Share 2 | - | 0.6000 | 0.3000 | 0.6300 | 0.7400 | - |
| Announcement Date | 4/15/22 | 4/9/23 | 4/15/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | 232 | -207 | 186 | 908 | - |
| ROE (net income / shareholders' equity) | - | 13.7% | 8.43% | 9.04% | 12.2% | 10.8% |
| ROA (Net income/ Total Assets) | - | 11.1% | 5.91% | 6.8% | 7.4% | 8% |
| Assets 1 | - | 8,278 | 10,362 | 10,618 | 15,128 | 12,850 |
| Book Value Per Share 2 | - | 12.80 | 13.30 | 14.30 | 16.30 | 17.10 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 785 | 724 | 630 | 560 | 270 |
| Capex / Sales | - | 13.73% | 13.53% | 10.67% | 7.44% | 3.72% |
| Announcement Date | 4/15/22 | 4/9/23 | 4/15/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
17.93
CNY
Average target price
23
CNY
Spread / Average Target
+28.28%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +2.11% | 1.38B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- 605507 Stock
- Financials Guobang Pharma Ltd.
